Guggenheim Maintains Buy on GRAIL, Raises Price Target to $155

10/1/2026
Impact: 85
Healthcare

Guggenheim analyst Subbu Nambi has maintained a 'Buy' rating on GRAIL (NASDAQ: GRAL) and raised the price target significantly from $75 to $155. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: